Pleasanton, CA, May 7, 2013 CooperVision is pleased to announce a Science and Technology (S&T) Awards Program. The goal of this awards program is to bring recipients and CooperVision scientists together to explore new areas of technology advancement. The awards program will address ocular surface health and anterior segment symptomology through advancement of technologies including, but not limited to materials, devices and compounds.
"Our goal is to support science and encourage a focus on unmet needs that can be translated back to our community. I am pleased that the CooperVision Science and Technology Awards will provide scientists in academia and research institutes a substantive opportunity to pursue emerging ideas and concepts in a meaningful and focused way,” said Arthur Back, Chief Technology Officer for CooperVision.
The CooperVision S&T Awards Program comprises of two awards: The CooperVision Seedling Award and the CooperVision Translational Research Award.
The CooperVision Seedling Award is intended to incentivize collaborations with CooperVision in a new research area for a one year period. This award enables investigators to generate preliminary data that could be used toward a future CooperVision Translational Research Award. Early-career and established faculty in areas other than contact lens research are strongly encouraged to apply. A CooperVision Seedling Award provides funding for one year and is awarded on a one-time basis only. The maximum total cash amount for a CooperVision seedling is $100,000, including indirect costs.
The CooperVision Translational Research Award is a multi-year award for a substantive translational research project. Early-career and established faculty in areas other than contact lens and research are strongly encouraged to apply. Collaboration between basic scientists, engineers and clinicians are strongly encouraged in order to achieve high-quality, innovative translational research. A CooperVision Translational Research Award provides funding for up to two years, totaling up to $400,000, including indirect costs. A maximum of $250,000 can be requested for any one year. A CooperVision Translational Research Award may be considered for renewal.
For information of the application process and materials, please visit us at http://coopervision.com/our-company/science-and-technology-awards.
CooperVision, a unit of The Cooper Companies, Inc. [NYSE: COO], is one of the world’s leading manufacturers of soft contact lenses. Dedicated to continually bringing a fresh perspective to the contact lens experience for practitioners and patients, CooperVision specialises in lenses for astigmatism, presbyopia, and ocular dryness. The company routinely collaborates with eye-care professionals in the research and development of relevant products. CooperVision manufactures a full array of monthly and daily disposable contact lenses featuring advanced materials and optics. For more information, visit www.coopervision.com.
Contact lenses are medical devices and can only be prescribed and dispensed by a licensed eye care professional.
About The Cooper Companies
The Cooper Companies, Inc. (“Cooper”) is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women’s health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has over 7,500 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.